AbbVie Q2 FY26: where the revenue came from and where it went
The whole income statement of AbbVie for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2026
- Reported
- Aug 3, 2026
Revenue$17.0B
+10% year over year
Gross profit$12.7B
75% margin
Operating profit$6.4B
38% margin
Net profit$3.6B
21% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 17.0 | 100% | +10% |
| Skyrizi | 5.5 | 32% | +24% |
| Neuroscience | 3.2 | 19% | +20% |
| Rinvoq | 2.5 | 15% | +25% |
| Oncology | 1.6 | 10% | −3% |
| Other revenue | 1.5 | 9% | |
| Aesthetics | 1.3 | 8% | +0% |
| Humira | 0.8 | 4% | −36% |
| Other key products | 0.6 | 3% | −28% |
| Cost of revenue | −4.3 | 25% | |
| Gross profit | 12.7 | 75% margin | +3pp |
| SG&A | −3.6 | 21% | +0pp |
| Other | −2.6 | 16% | |
| Operating profit | 6.4 | 38% margin | +6pp |
| Interest & other costs | −2.2 | ||
| Tax | −0.7 | ||
| Net profit | 3.6 | 21% margin | +15pp |
181 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest